Spiriva® Assessment of FEV1 (SAFE)

Summary

The objective of this trial is to evaluate whether the effect of one year (48 weeks) treatment with inhaled tiotropium bromide (Spiriva® - 18 µg once daily) on the change in trough FEV1, compared to placebo in patients with COPD, is affected by smoking status.

Timeline

Start

2002-01

Primary completion

2004-05

Completion

2004-05

Drugs

Indications